ReviewBone marrow transplantation2015
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Review in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.Annals of hematology · 2021Pooled it
- The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.Bone marrow transplantation · 2017Trial
- Article
- Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2023Article
- Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.Haematologica · 2023Article
- Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation.Leukemia research reports · 2023Review
- Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.Journal of cancer research and clinical oncology · 2022Article
- Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.Frontiers in oncology · 2020Review
- Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.International journal of hematology · 2018Article
- Article
- Article
- Chart review across EU5 in MM post-ASCT patients.International journal of hematologic oncology · 2018Article
- Article
- Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.Haematologica · 2017Article
- Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Blood cancer journal · 2017Review
- Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Therapeutic advances in hematology · 2017Review
- Review
- Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.The Korean journal of internal medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel agents including proteasome inhibitors and immunomodulatory drugs are now routinely utilized as part of the induction regimen before transplantation and this has resulted in substantial improvements in the depth of response achieved before transplant. Given that depth of response is prognostic for overall outcome, a number of studies have been conducted or are ongoing to investigate the use of novel agents as consolidation and maintenance therapy after transplant. Most clinical trials have reported after consolidation and maintenance therapy an increased PFS and even overall survival in some of them. The use of post-autologous stem cell transplant consolidation and maintenance is an increasingly attractive concept. However, some side effects could be observed with such long-term therapy and many open questions are still under debate. The decision to administer consolidation and/or maintenance therapy will likely need to be guided by the individual patient situation. This review aims to analyze the currently available research evidence in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.